What is soft tissue sarcoma?
Soft tissue sarcoma includes many distinct histologies, such as liposarcoma, leiomyosarcoma, undifferentiated pleomorphic sarcoma, synovial sarcoma, angiosarcoma, and malignant peripheral nerve sheath tumor. Gastrointestinal stromal tumor is a specialized sarcoma with its own molecular testing and treatment. Tumors may be superficial or deep and can arise in an extremity, chest wall, abdomen, retroperitoneum, head and neck, uterus, or other organ. Most have no known cause. Risk factors for selected cases include prior radiation, inherited syndromes, chronic lymphedema, and rare chemical exposures. Spread occurs most often through the bloodstream to the lungs, although patterns vary by subtype. Because an unplanned removal can leave contaminated tissue planes or inadequate margins, imaging and biopsy should precede excision of a suspicious mass. Expert pathology review can prevent treatment based on an incorrect subtype. Care depends on histologic subtype, anatomic site, depth, size, grade, stage, resectability, molecular biomarkers, age, and overall health.
Signs and symptoms
A painless lump or swelling that grows over time is the most common presentation. A deep tumor may not be visible and can become large before causing pressure, aching, numbness, weakness, or reduced movement. Abdominal or retroperitoneal sarcoma may cause pain, fullness, early satiety, constipation, vomiting, urinary changes, or bleeding. A tumor in the chest can produce cough, shortness of breath, or chest discomfort. Uterine sarcomas may cause abnormal bleeding or pelvic pressure. Most lumps are benign lipomas, cysts, bruises, or other noncancer conditions, and most pain has a musculoskeletal cause. Assessment is especially important for a mass that is enlarging, deep to fascia, firm, painful, recurrent after removal, or roughly golf-ball sized or larger. Symptoms vary by site and are not diagnostic; persistent or progressive changes warrant imaging and clinical evaluation.
Diagnosis and staging
Ultrasound may help characterize some superficial masses, but MRI is usually preferred for extremity, trunk, or pelvic tumors. CT is often used for retroperitoneal, abdominal, or chest tumors and for chest staging. Biopsy should be planned jointly with the sarcoma surgeon or multidisciplinary team; image-guided core biopsy usually provides tissue while preserving future surgical options. Pathology determines histology and grade using morphology, immunohistochemistry, and selected cytogenetic or molecular tests for gene fusions or mutations. Expert review is important because subtypes can look alike but require different care. Staging considers tumor size, depth or site, grade, regional nodes for selected histologies, and distant metastases, commonly in lungs. PET or other imaging is used selectively. Baseline function and organ health help plan treatment. Care depends on subtype, site, grade, stage, resectability, biomarkers, age, and overall health, and changed behavior may justify repeat biopsy.
Established treatment paths
For many localized soft tissue sarcomas, the main treatment is wide surgical excision with negative margins and preservation of function when possible. Radiation before or after surgery is often considered for intermediate- or high-grade, deep, large, or anatomically constrained tumors to improve local control. Definitive radiation may be used when surgery would cause unacceptable harm or cannot be performed. Chemotherapy is not routine for every localized adult sarcoma; its role depends on histology, recurrence risk, resectability, and patient factors. Doxorubicin-based therapy is a common systemic foundation for advanced disease, while other agents are chosen by subtype and prior exposure. Targeted therapy is central for KIT- or PDGFRA-driven gastrointestinal stromal tumors and useful in selected other molecular settings. Immunotherapy benefits a limited subset of histologies or biomarker-defined tumors. Recurrent or metastatic disease may be treated with systemic therapy, surgery or focused radiation for limited sites, symptom-directed care, or clinical trials. Care depends on subtype, grade, stage, molecular biomarkers, prior treatment, age, organ function, and goals. Follow-up strategy reflects the tumor’s grade, site, lung-spread risk, and expected recurrence pattern.
Supportive care
Supportive care aims to preserve movement, strength, and independence. Physical and occupational therapy, compression or lymphedema care, wound support, prosthetics, and pain management may be needed after limb or pelvic treatment. Teams address nausea, low blood counts, fatigue, nerve symptoms, skin effects, nutrition, sleep, and emotional distress. Fertility preservation can be discussed before chemotherapy or pelvic radiation. Palliative care supports symptom relief and decisions alongside active treatment, including for advanced disease. Follow-up typically includes examination plus local and chest imaging based on subtype, grade, and recurrence pattern. New or enlarging lumps should be reported. Supplements and medicines should be reviewed for interactions, bleeding risk, and effects around surgery or systemic therapy.
Profiles documenting soft tissue sarcoma care
These profiles mention a matching cancer specialty in their published materials. Browse their locations, reported services, and practical details.
No clinic profile is connected to this guide yet. The wider directory may still offer useful places to explore.
Sources
Source information checked: 2026-09-29. The links below identify the public and clinic-provided materials used for this page.
- NCI: Soft Tissue Sarcoma Treatment ↗Checked 2026-09-29
- NCI: Soft Tissue Sarcoma—Patient Version ↗Checked 2026-09-29
How Cancer Clinic Finder compiles information · Suggest a factual correction
